University Hospital Zurich
Zurich, 8091, Switzerland
NCT Number: NCT03522519
Poststroke recovery mainly takes place within the first weeks to months and about 95% of the patients reach their maximum recovery 3 months after stroke onset. Poststroke rehabilitation is initiated as early as possible and aims to reduce functional consequences of stroke, allowing patients to integrate into the community. However, up to 75% of the patients remain disabled in the long term. Strikingly, about 20 to 30% of the patients show functional decline (i.e., learned-nonuse) in the long term - most often after having finished their intensive rehabilitation period - and even stroke survivors who have little or no residual disability are less physically active when compared to their age-matched peers.
Poststroke outcomes can be well predicted early after stroke. However, the deficits early after stroke and the outcomes are measured by standardized clinical tests performed in the laboratory. The drawback of these tests is that they provide information about the best possible abilities of the patients, as they are encouraged by therapists in testing situations. This so called "capacity" does not necessarily reflect what patients do in daily life situations (i.e., "performance" or "real world use").
With the growing interest in the patients' performance, various assessments that objectively measure activities in daily life situations have been developed in the last few years. These devices capture movement in daily life situations in a sensitive and objective way. An additional benefit is that they are less hampered by floor or ceiling effects when compared to clinical laboratory measurements (i.e., clinimetrics). Nevertheless, outcome of real world performance is hardly ever used in clinical trials aiming to determine the effectiveness of stroke rehabilitation interventions. Actually, until today, the natural course of performance remains largely unknown, as are predictors for this course. It is also unknown to which extend patients' subjective reporting of performance matches objectively measured performance. Finally, although it is believed that there is a threshold for, for example, real life use of the paretic arm and further improvement, there is no evidence as to what this threshold is in terms of clinical laboratory measurements.
The present prospective longitudinal cohort study fills in the gap regarding knowledge about the profile and predictability of two performance outcomes during the first year poststroke: engagement in physical activities and the use of the paretic upper limb. In addition, it will provide insight in how physical activity engagement and upper limb use measured by daily life assessments relate to standard clinical laboratory assessments. This knowledge is a prerequisite for the identification of patients' phenotypes and a first essential step towards the development of tailored (i.e., precision medicine), innovative rehabilitation interventions which enhance performance in terms of physical activities or upper limb use in daily life. The ultimate goal is to reduce poststroke disability and associated costs.
RE-USE is a prospective longitudinal observational cohort study of 120 first-ever stroke patients, who will be assessed 3, 10, 28, 90 and 365 days after stroke onset, as well as at discharge of the rehabilitation center.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Zurich, 8091, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will be assessed by using movement sensors and standard clinical assessments
Time frame: 90 days after stroke onset
Real world performance, measured with movement sensors (number)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
National Institutes of Health Stroke Scale (0-42 points, lower scores being better)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Fugl-Meyer Assessment (0-66 points, higher scores being better)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Motricity Index (0-200 points, higher scores being better)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Trunk Control Test (0-100 points, higher scores being better)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Berg Balance Scale (0-56 points, higher scores being better)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Functional Ambulation Categories (0-5 points, higher scores being better)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Ten-Meter Walk Test
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Action Research Arm Test (0-56 points, higher scores being better)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Box and Block Test (number of blocks)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Modified Rankin Scale (0-6 points, lower scores being better)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Fatigue Severity Scale (9-63 point, lower scores being better)
Time frame: 3 and 90 days after stroke onset
Montreal Cognitive Assessment(0-30 points, higher scores being better)
Time frame: 3 and 90 days after stroke onset
Apples Test (number)
Time frame: 90 and 365 days after stroke onset
International Physical Activity Questionnaire (3 levels higher levels are better)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Motor Activity Log - 14 item version (0-5 points, higher scores being better)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Global Rating of Perceived Changes (1-7 points, higher scores being better; 1-10 points, lower scores being better)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Intensity of therapy based on charts (minutes)
Time frame: 3, 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Serious Events (1. death; 2. life-threatening illness or injury; 3. in-patient or prolonged hospitalisation; 4. medical or surgical intervention to prevent life threatening illness; 5. led to fetal distress, death or a congenital abnormality or birth defect) and non-serious infections or cardiovascular events
Time frame: 3, 10, 28 (expected rehabilitation discharge) and 365 days after stroke onset
Real world performance, measured with movement sensors (number)
Time frame: 10, 28, 90 (expected rehabilitation discharge) and 365 days after stroke onset
Hospital Anxiety and Depression Scale (0-42 points, higher scores indicate greater levels of anxiety or depression)
Time frame: 365 days after stroke onset
Health care costs and loss of income in relation to the stroke (CHF)
University of Zurich
Other
Profiling and Predicting the Natural Course of Real World Physical Activity and Upper Limb Use After Stroke
Acronym: REUSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT07276477
Behavior, Brain Diseases
Uşak, Turkey (Türkiye)
View Trial DetailsNCT06597929
Behavior, Brain Diseases
Barcelona, Catalonia, Spain
View Trial DetailsNCT04238260
Behavior, Brain Diseases
Vancouver, British Columbia, Canada
View Trial Details